Victory Capital Management
ZVRA icon

Victory Capital Management’s Zevra Therapeutics ZVRA Stock Holding History

Victory Capital Management’s Portfolio ZVRA Stock Details ZVRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$506K Buy
+54,251
New +$489K ﹤0.01% 2033
2020
Q2 		– Sell
-1,040
Closed -$4K – 3318
2020
Q1 		$4K Buy
+1,040
New +$5.75K ﹤0.01% 3566
2019
Q4 		– Sell
-288
Closed -$3K – 3309
2019
Q3 		$3K Buy
+288
New +$5.21K ﹤0.01% 3583
2019
Q2 		– Sell
-2,605
Closed -$70K – 1866
2019
Q1 		$70K Sell
2,605
-12,482
-83% -$459K ﹤0.01% 1684
2018
Q4 		$430K Buy
15,087
+4,936
+49% +$200K ﹤0.01% 1401
2018
Q3 		$780K Sell
10,151
-516
-5% -$40.3K ﹤0.01% 1316
2018
Q2 		$1.11M Sell
10,667
-567
-5% -$55.4K ﹤0.01% 1232
2018
Q1 		$1.42M Buy
11,234
+1,104
+11% +$107K ﹤0.01% 1162
2017
Q4 		$656K Buy
10,130
+2,132
+27% +$129K ﹤0.01% 1296
2017
Q3 		$473K Sell
7,998
-163
-2% -$8.68K ﹤0.01% 1331
2017
Q2 		$522K Sell
8,161
-93
-1% -$6.13K ﹤0.01% 1306
2017
Q1 		$647K Buy
+8,254
New +$501K ﹤0.01% 1256

Other funds holding ZVRA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Legal & General Group
Legal & General Group London, United Kingdom $432B AUM 29.4% 1-Year Est. Return

Victory Capital Management's ZVRA Position: Q1 2026 in Review

Victory Capital Management opened a new position in Zevra Therapeutics (ZVRA) in Q1 2026: 54,251 shares worth $506K. The stake represents ﹤0.01% of the portfolio and ranks #2033 among its holdings. This is a return to the name: Victory Capital Management previously reported a position in ZVRA as recently as Q1 2020.

Victory Capital Management first reported a position in ZVRA in Q1 2017 and has held it in 12 quarters since. The position peaked at $1.42M in Q1 2018. 148 funds tracked by Wall St. Rank hold ZVRA as of Q1 2026.

  • Victory Capital Management held 54,251 shares of Zevra Therapeutics worth $506K as of Q1 2026.
  • Zevra Therapeutics was a new Victory Capital Management position in Q1 2026.
  • Zevra Therapeutics made up ﹤0.01% of Victory Capital Management's portfolio in Q1 2026, its #2033 holding.
  • Victory Capital Management first reported a position in Zevra Therapeutics in Q1 2017 and has held it in 12 quarters since.
  • Victory Capital Management's Zevra Therapeutics position peaked at $1.42M in Q1 2018.
  • 148 funds tracked by Wall St. Rank held Zevra Therapeutics as of Q1 2026.

Based on Victory Capital Management's 13F filing for Q1 2026, filed 15 May 2026.